These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31965542)

  • 1. Conjunctival Melanoma: Current Treatments and Future Options.
    Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
    Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Zhou AY; Johnson DB
    Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of BRAF-mutated, bulbar conjunctival melanoma, and review of the published literature.
    Kiyohara T; Tanimura H; Miyamoto M; Shijimaya T; Nagano N; Nakamaru S; Makimura K; Iwai H
    Clin Exp Dermatol; 2020 Mar; 45(2):207-211. PubMed ID: 31361915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
    Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma: smart therapeutic strategies in immuno-oncology.
    Eggermont AM; Robert C
    Nat Rev Clin Oncol; 2014 Apr; 11(4):181-2. PubMed ID: 24590131
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
    Swe T; Kim KB
    Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
    Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
    Front Immunol; 2019; 10():990. PubMed ID: 31134073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients.
    Sheng X; Li S; Chi Z; Si L; Cui C; Mao L; Lian B; Tang B; Wang X; Yan X; Kong Y; Dai J; Guo J
    Br J Ophthalmol; 2015 Jul; 99(7):990-6. PubMed ID: 25595173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
    Schaefer T; Satzger I; Gutzmer R
    Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapies for Melanoma: A New Standard of Care?
    Smalley KS; Eroglu Z; Sondak VK
    Am J Clin Dermatol; 2016 Apr; 17(2):99-105. PubMed ID: 26860106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
    Miller DM; Flaherty KT; Tsao H
    Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Metastatic Melanoma in 2018.
    Kaufman HL; Margolin K; Sullivan R
    JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical treatment options for early-stage and advanced conjunctival melanoma.
    Zeng Y; Hu C; Shu L; Pan Y; Zhao L; Pu X; Wu F
    Surv Ophthalmol; 2021; 66(3):461-470. PubMed ID: 32980421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
    Meng D; Carvajal RD
    Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.